The CenterWatch Weekly, September 05, 2017
Innovo Research, QuintilesIMS form new model for clinical trials
Innovo Research, a new venture started by Wilmington Health, the Christie Clinic and QuintilesIMS, a global leader in healthcare intelligence, will build a robust network of high-performing accountable care organizations (ACOs). A key benefit of this arrangement will be a larger pool of clinical trials patients to draw on. ACOs are particularly well-suited to serve as the foundation of this new nationwide network. By definition, ACOs are a collaborative group committed to providing high-quality, coordinated care to their patients. To that end, the electronic medical records (EMRs) of all patients are connected, resulting in access to patient information on the part of all the providers in the network.
FDA increases enforcement, policy steps against unproven stem cell therapies
Scott Gottlieb, M.D., the Commissioner of the FDA, has stated that the agency is beginning to enforce stricter and more aggressive tactics against stem cell clinics who are marketing and administrating unproven therapies to patients. The administration will work toward cracking down on companies who claim to have cures or treatments for diseases that have no conclusive clinical efficacy.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.